CS/HB 505 — Florida Comprehensive Drug Abuse Prevention and Control Act
by Criminal Justice Subcommittee and Rep. Trumbull and others (CS/SB 1002 by Criminal Justice Committee and Senators Perry, Rouson, and Bradley)
This summary is provided for information only and does not represent the opinion of any Senator, Senate Officer, or Senate Office.
Prepared by: Criminal Justice Committee (CJ)
The bill amends Florida’s controlled substance schedules to provide that ioflupane I 123, a radiopharmaceutical used in the diagnosis of Parkinsonian syndromes, is not a Schedule II controlled substance. Without this change, ioflupane I 123 would be a Schedule II controlled substance because it is derived from cocaine via ecgonine, both of which are Schedule II controlled substances.
The bill also provides that cross-references throughout the Florida Statutes to the Florida Comprehensive Drug Abuse Prevention and Control Act (ch. 893, F.S.), or any portion thereof, include all subsequent amendments to the act.
If approved by the Governor, these provisions take effect July 1, 2017.
Vote: Senate 37-0; House 112-0